

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 14. (Cancelled)
15. (Previously Presented) A composition for raising an immune response comprising an HIV antigen and an immunostimulatory CpG oligonucleotide.
16. (Previously Presented) A composition as claimed in claim 15 wherein the antigen is selected from the group consisting of HIV antigens, gp120, gp160, Nef, Tat, Nef-Tat fusions and immunologically equivalent derivatives thereof.
17. (Previously Presented) A composition as claimed in claim 15 wherein the antigen is fused to Protein D, or lipoprotein D or a fragment thereof, from Haemophilus influenzae.
18. (Previously Presented) A composition as claimed in claim 15 wherein the antigen comprises a Nef-Tat fusion protein.
19. (Previously Presented) A composition as claimed in claim 15 further comprising an aluminum salt.
20. (Previously Presented) A composition as claimed in claim 15 further comprising a saponin adjuvant.
21. (Previously Presented) A composition as claimed in claim 15 wherein the oligonucleotide comprises two CpG dinucleotides.
22. (Previously Presented) A composition as claimed in claim 15 wherein the CpG oligonucleotide is between 15-45 nucleotides in length.
23. (Previously Presented) A composition as claimed in claim 15 wherein the CpG oligonucleotide comprises at least one phosphorothioate internucleotide bond.
24. (Currently Amended) A composition as claimed in claim 15 wherein the oligonucleotide is selected from the group consisting of oligonucleotides designated as WD1001

Int'l. Appln. No.: PCT/EP00/05998

Docket No. B45186

(SEQ ID NO:1), WD1002 (SEQ ID NO:2), WD1003 (SEQ ID NO:3), WD1004 (SEQ ID NO:4),
WD1005 (SEQ ID NO:5), WD1006 (SEQ ID NO:6), and WD1007 (SEQ ID NO:7).

25. (Previously Presented) A method for the prevention or amelioration of HIV infection in a patient, comprising administering an effective amount of a vaccine as claimed in claim 15 to the patient.

26. (Previously Presented) A method for the prevention or amelioration of HIV infection in a patient, comprising administering an effective amount of a vaccine as claimed in claim 19.

27. (Previously Presented) A method for the prevention or amelioration of HIV infection in a patient, comprising administering an effective amount of a vaccine as claimed in claim 20

28. (Previously Presented) A method of producing a vaccine as claimed in claim 15 comprising admixing an HIV antigen and a CpG immunostimulatory oligonucleotide.

29. (Previously Presented) A method for the prevention or amelioration of HIV infection in a patient, comprising administering an effective amount of a CpG oligonucleotide followed after a suitable time by an effective amount of an HIV antigen.